Online citations, reference lists, and bibliographies.
← Back to Search

Application Potential Of Engineered Liposomes In Tumor Targeting

Ankit Jain, S. Jain
Published 2017 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Most anticancer agents are poorly water soluble and highly potent by nature, leading to nonselective devastation of tumor, as well as normal healthy cells; this poses an obstinate challenge in safe and effective tumor chemotherapy. To get the better of this debilitating problem, liposomes have emerged as revolutionary cargoes, in last few decades, with successful rates on the rise in tumor targeting. Their extraordinary capability to carry both hydrophilic and hydrophobic bioactives in separate domains of residence and amenability to surface and compositional engineering destine this vesicular system to come true the “magic bullet concept” which was enunciated by the great biologist Paul Ehrlich. Enhanced permeability and retention effect and tumor specific ligands mediate passive targeting and active targeting to tumors, respectively. The stealth effect attributed to PEGylation in liposomes has opened up new horizons in prolonged drug delivery, and proved to be a promising tactic to solve safety issues associated with active targeting principles. Current scenarios in liposomes fabrication techniques bring forth environmentally responsive features (pH, temperature, and photosensitivity, etc.) to facilitate enhanced localization at the tumor site, in addition to targeting capabilities. This chapter sums up the drug targeting potential of the engineered liposomes, with contemporary trends in the field of liposomal research.
This paper references
10.1089/CBR.2005.20.620
Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation.
Changmoon Lee (2005)
10.2174/1566524015666150831131320
Colon Targeted Liposomal Systems (CTLS): Theranostic Potential.
A. Jain (2015)
10.1155/2011/160515
Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands
Oula Penate Medina (2011)
10.1016/j.yexmp.2010.01.006
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv.
Kristin S. Loomis (2010)
10.1081/LPR-100108459
POLY(HPMA)-COATED LIPOSOMES DEMONSTRATE PROLONGED CIRCULATION IN MICE
K. Whiteman (2001)
10.1158/1535-7163.MCT-13-1004
Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells
X. Xie (2014)
10.1021/nn9018587
Stimuli-responsive liposome fusion mediated by gold nanoparticles.
Dissaya Pornpattananangkul (2010)
10.4155/TDE.12.38
Liposomes and inorganic nanoparticles for drug delivery and cancer imaging.
C. Heneweer (2012)
10.1021/bc300175d
Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging.
S. Li (2012)
10.1016/j.apradiso.2011.04.019
The radiobiological principles of boron neutron capture therapy: a critical review.
J. Hopewell (2011)
10.1016/S0927-7765(99)00156-3
'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.
Gref (2000)
10.1007/s00280-011-1664-2
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
N. M. La-Beck (2011)
10.1093/protein/gzu020
Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.
D. Bedi (2014)
10.1002/cmmi.1572
Absolute MR thermometry using nanocarriers.
Roel Deckers (2014)
10.1016/j.jconrel.2010.03.007
Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
X. Chen (2010)
10.1016/j.biomaterials.2010.10.050
Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy.
K. Kono (2011)
10.1016/j.nano.2010.12.010
Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA.
Federico Perche (2011)
10.1007/s11095-007-9425-y
Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells
T. Yang (2007)
10.1016/0005-2736(93)90039-3
Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times.
G. Blume (1993)
10.1615/CRITREVTHERDRUGCARRIERSYST.2016015926
Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform.
Shivani Saraf (2016)
10.1016/j.cell.2011.09.024
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Scott Valastyan (2011)
10.3109/10717544.2014.903580
A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma
Wen-bing Dai (2015)
10.1055/s-0033-1355335
The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer.
M. Yuan (2014)
10.1016/j.nano.2011.02.001
Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model.
Man-Yi Wong (2011)
10.1096/fj.06-6186fje
Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production
S. Moein Moghimi (2006)
10.1007/s00280-007-0525-5
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
A. Gabizon (2007)
10.3322/caac.20114
Photodynamic therapy of cancer: An update
P. Agostinis (2011)
10.1016/j.ejpb.2010.04.012
Distearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery.
T. J. Evjen (2010)
10.1080/1061186021000072447
Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine Models
A. Gabizon (2002)
10.1016/j.jconrel.2012.06.019
Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
K. Takara (2012)
10.1016/S0378-5173(02)00129-1
Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating.
T. Levchenko (2002)
10.3109/10717544.2014.907373
Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma
Divya Bansal (2016)
10.1016/j.biomaterials.2014.04.087
An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
Mst. Naznin Ara (2014)
10.3109/03639045.2015.1036066
Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer
Ankit Jain (2016)
10.1016/j.jconrel.2011.06.001
Targeted drug delivery to tumors: myths, reality and possibility.
Y. Bae (2011)
10.1016/j.biomaterials.2014.03.036
Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Wenbing Dai (2014)
10.3109/1061186X.2013.875029
Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery
J. Tang (2014)
10.1182/BLOOD-2006-04-014878
Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4.
E. Ihanus (2007)
10.1016/j.biomaterials.2010.05.045
Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy.
K. Kono (2010)
10.1016/j.biomaterials.2014.04.031
Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering.
Zhaoming Guo (2014)
10.4155/tde.14.14
Penetrating the cell membrane, thermal targeting and novel anticancer drugs: the development of thermally targeted, elastin-like polypeptide cancer therapeutics.
Jung Su Ryu (2014)
10.1016/j.jconrel.2011.09.085
Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy.
M. Bovis (2012)
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors.
R. Campbell (2002)
10.1007/s11095-011-0569-4
Cationic Liposomal Co-delivery of Small Interfering RNA and a MEK Inhibitor for Enhanced Anticancer Efficacy
S. H. Kang (2011)
10.1227/NEU.0b013e31820b52aa
Computed Tomography Imaging of Transferrin Targeting Liposomes Encapsulating Both Boron and Iodine Contrast Agents by Convection-Enhanced Delivery to F98 Rat Glioma for Boron Neutron Capture Therapy
S. Miyata (2011)
10.1016/j.jconrel.2012.10.008
Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes.
Morten B. Hansen (2012)
10.1021/ar200105p
Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.
Wafa’T. Al-Jamal (2011)
10.1016/j.jconrel.2010.10.036
Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study.
M. de Smet (2011)
10.1016/j.ijpharm.2011.08.034
Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: benefits over classical vesicles.
E. Ducat (2011)
10.1158/1078-0432.CCR-05-1664
The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors
Andrew J Primeau (2005)
10.1038/cgt.2008.79
Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA
M. Mikhaylova (2009)
10.3109/1061186X.2010.550920
In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein
T. Wang (2011)
10.1158/0008-5472.CAN-09-2821
Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.
C. Grange (2010)
10.1016/j.biomaterials.2014.03.046
pH-responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy.
Yi-Ting Chiang (2014)
10.1074/JBC.M207500200
Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif*
G. Colombo (2002)
10.1080/10611860802368966
RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer
H. Zhao (2009)
10.1016/j.addr.2010.09.001
A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma.
H. Hatakeyama (2011)
10.1016/j.ijpharm.2014.04.008
Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Ling Mei (2014)
10.1158/1078-0432.CCR-07-4530
Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth
F. Doñate (2008)
10.1007/s00280-014-2476-y
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide
Wendi V. Rodrigueza (2014)
10.1016/j.ijpharm.2012.04.030
Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
S. Malhi (2012)
α-Fe2O3ナノ構造体の形状制御合成:改良した光触媒分解効率のための表面特性の加工
S. Bharathi (2013)
10.3109/08982104.2014.928890
cRGD-conjugated magnetic-fluorescent liposomes for targeted dual-modality imaging of bone metastasis from prostate cancer
F. Wang (2015)
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.
K. Harrington (2001)
10.1038/nnano.2007.387
Nanocarriers as an emerging platform for cancer therapy.
D. Peer (2007)
10.1016/j.chemphyslip.2016.10.005
IN VITRO RELEASE KINETICS MODEL FITTING OF LIPOSOMES: AN INSIGHT.
Ankit Jain (2016)
10.1016/j.biomaterials.2014.03.077
The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3.
C. Qin (2014)
10.1016/j.biomaterials.2009.01.026
Reduction-sensitive polymers and bioconjugates for biomedical applications.
F. Meng (2009)
10.1021/nn405839n
Hyaluronan Polymer Length, Grafting Density, and Surface Poly(ethylene glycol) Coating Influence in Vivo Circulation and Tumor Targeting of Hyaluronan-Grafted Liposomes
H. S. Qhattal (2014)
10.1073/pnas.0435906100
Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome–DNA complexes
V. Torchilin (2003)
10.1080/10611860802229978
Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer
Kimberley M Laginha (2008)
10.1016/j.jconrel.2011.10.037
State of the art in PEGylation: the great versatility achieved after forty years of research.
G. Pasut (2012)
10.1021/mp1000235
A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
Junlin Zhang (2010)
10.1016/j.canlet.2009.06.008
A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy.
Yuki Murase (2010)
10.1016/j.biomaterials.2014.01.035
Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Yunfei Wang (2014)
10.1016/J.IJPHARM.2007.02.011
Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.
T. Yang (2007)
10.1016/j.biomaterials.2012.08.031
The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer.
Z. Wang (2012)
10.1615/CRITREVTHERDRUGCARRIERSYST.2015010903
Ligand-Appended BBB-Targeted Nanocarriers (LABTNs).
Ankit Jain (2015)
10.2217/nnm.10.30
Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.
T. Wang (2010)
10.1016/j.jconrel.2012.05.043
Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor.
Sangbin Lee (2012)
10.1038/5289
Cancer multidrug resistance
A. Persidis (1999)
10.1016/j.biochi.2014.07.022
On the importance of electrostatic interactions between cell penetrating peptides and membranes: a pathway toward tumor cell selectivity?
Marie-Lise Jobin (2014)
10.1007/s00280-006-0356-9
The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men
M. Triesscheijn (2006)
10.1016/S0360-3016(02)03928-7
Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy.
S. Ran (2002)
10.1007/s002800050855
Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice
M. S. Newman (1999)
10.2147/DDDT.S63235
Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro
B. C. Wong (2014)
10.1002/cbic.200700727
Synthesis and Transfection Activity of New Cationic Phosphoramidate Lipids: High Efficiency of an Imidazolium Derivative
Mathieu Mével (2008)
10.1021/mp400718j
Enhancement of the uptake and cytotoxic activity of doxorubicin in cancer cells by novel cRGD-semipeptide-anchoring liposomes.
L. Battistini (2014)
10.1016/j.jconrel.2010.09.020
Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo.
G. D. Kenny (2011)
10.1158/1078-0432.CCR-08-2392
Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody
T. Elbayoumi (2009)
10.1158/1078-0432.CCR-03-0041
Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments
P. Sapra (2004)
10.1007/s11095-014-1418-z
Folate and TAT Peptide Co-Modified Liposomes Exhibit Receptor-Dependent Highly Efficient Intracellular Transport of Payload In Vitro and In Vivo
Yaqin Zhu (2014)
10.1371/journal.pone.0092924
Co-Delivery of Doxorubicin and SATB1 shRNA by Thermosensitive Magnetic Cationic Liposomes for Gastric Cancer Therapy
Zhao Peng (2014)
10.1021/mp400759d
Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
M. Liu (2014)
10.1016/J.JCONREL.2007.11.002
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles.
Shyh-Dar Li (2008)
10.1158/1078-0432.CCR-08-3285
Cancer-Selective Targeting and Cytotoxicity by Liposomal-Coupled Lysosomal Saposin C Protein
X. Qi (2009)
10.3109/10717544.2013.853850
A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects
J. Tian (2014)
10.1016/j.jconrel.2009.10.023
Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo.
Y. Obata (2010)
10.1007/s10549-008-9948-x
Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes
T. Kikumori (2008)
10.3109/08982104.2010.520273
Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals
Y. Wu (2011)
10.1016/j.jconrel.2014.05.036
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
Charlene M. Dawidczyk (2014)
10.1201/B19867-9
P-gp Inhibitors: A Potential Tool to Overcome Drug Resistance in Cancer Chemotherapy
Ankit Jain (2016)
10.1088/0031-9155/53/9/R01
The physics, biophysics and technology of photodynamic therapy.
B. Wilson (2008)
10.1007/s11051-013-1772-5
Dual drug delivery using “smart” liposomes for triggered release of anticancer agents
Ankit Jain (2013)
10.1038/nrd1632
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
10.1073/PNAS.84.15.5444
Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation.
M. Weiss (1987)
10.1615/CRITREVTHERDRUGCARRIERSYST.2013007706
Nano-aggregates: emerging delivery tools for tumor therapy.
V. K. Sharma (2013)
10.1177/096032719901800103
Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs
M. Amantea (1999)
10.1158/0008-5472.CAN-11-1432
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.
M. Zigler (2011)
10.2147/IJN.S34652
Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity
E. A. Leite (2012)
10.1002/jps.21458
Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics.
R. Campbell (2009)
10.18632/ONCOTARGET.261
Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting
A. Mann (2011)
10.1016/S0169-409X(01)00232-0
Phototriggering of liposomal drug delivery systems.
P. Shum (2001)
10.1016/0014-5793(91)80699-4
Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo
A. Mori (1991)
10.1016/j.biomaterials.2011.03.015
Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Jean-Sébastien Thomann (2011)
10.1158/1078-0432.CCR-08-0233
TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis
W. Yang (2008)
10.1080/10611860701498203
Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes
A. Kale (2007)
10.1016/j.ejpb.2010.01.002
Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Y. Zhang (2010)
10.1016/j.jconrel.2011.06.043
In situ dose amplification by apoptosis-targeted drug delivery.
K. Wang (2011)
10.2147/IJN.S60178
Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting
P. Ye (2014)
10.1016/j.bbamem.2010.12.014
Do folate-receptor targeted liposomal photosensitizers enhance photodynamic therapy selectivity?
M. García-Diaz (2011)
10.1021/mp3002733
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.
F. Danhier (2012)
10.1002/jps.21358
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
D. Drummond (2008)
10.1016/j.chemphyslip.2009.08.003
Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes.
Avi Schroeder (2009)
10.3858/emm.2008.40.6.617
Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity
J. Hu (2008)
10.1016/j.nano.2012.01.003
Peptide PHSCNK as an integrin α5β1 antagonist targets stealth liposomes to integrin-overexpressing melanoma.
Wenbing Dai (2012)
10.1016/j.jconrel.2014.04.050
In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes.
R. Rüger (2014)
10.1042/BJ20140173
Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy.
Ruiyang Yan (2014)
10.1016/j.jconrel.2014.03.043
Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice.
L. Zhang (2014)
10.1016/j.bbamem.2012.07.011
Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods.
K. Yoshino (2012)
10.1016/j.addr.2010.09.003
Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.
K. Maruyama (2011)
10.1016/j.addr.2010.04.009
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
J. Fang (2011)
10.1016/j.jconrel.2009.03.007
Ultrasound triggered release of cisplatin from liposomes in murine tumors.
A. Schroeder (2009)
10.1007/s11095-014-1404-5
Hyperthermia Sensitization and Proton Beam Triggered Liposomal Drug Release for Targeted Tumor Therapy
R. Fernando (2014)
10.1002/ijc.27441
Tumor–platelet interaction in solid tumors
D. Buergy (2012)
10.2147/IJN.S29242
Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent
A. Accardo (2012)
10.1021/ar200256e
Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides.
I. Nakase (2012)
10.1016/j.bbrc.2008.01.074
Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown.
T. Asai (2008)
10.1016/j.biomaterials.2014.01.076
PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Y. Yang (2014)
10.1021/la302433a
Superhydrophilic zwitterionic polymers stabilize liposomes.
Z. Cao (2012)
10.1158/1078-0432.CCR-09-3199
Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non–Hodgkin's Lymphoma Xenograft Mouse Model
J. Tuscano (2010)
10.2147/IJN.S33965
Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma
Xiaoju Zhou (2012)
10.1016/j.jconrel.2014.01.005
Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.
Eric E. Paoli (2014)
10.3109/1061186X.2012.723215
A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse
Y. Maitani (2012)
10.1016/j.addr.2012.09.037
Liposomal drug delivery systems: from concept to clinical applications.
T. Allen (2013)
10.2217/NNM.13.66
Liposomes containing NY‑ESO‑1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines.
L. Cruz (2014)
10.1016/J.JCONREL.2007.11.009
The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats.
T. Ishida (2008)
10.1158/0008-5472.CAN-08-2397
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
G. Villares (2008)
10.1016/j.ijpharm.2008.11.023
Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation.
J. Wenzel (2009)
10.1016/j.jconrel.2012.07.013
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
S. Taurin (2012)
10.1016/j.bbamem.2010.07.030
A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of doxorubcin to cells.
Amichai Yavlovich (2011)
10.1021/bc300266y
Acid-triggered release via dePEGylation of fusogenic liposomes mediated by heterobifunctional phenyl-substituted vinyl ethers with tunable pH-sensitivity.
Hee-Kwon Kim (2012)
10.1016/j.jconrel.2008.05.024
Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
M. Saad (2008)
10.2174/1389450117666160208144143
Stimuli-responsive Smart Liposomes in Cancer Targeting.
Ankit Jain (2018)
10.1016/j.addr.2012.09.003
Liposome imaging agents in personalized medicine.
A. L. Petersen (2012)
10.1016/j.jss.2014.02.021
Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor.
Matthew R. Zeiderman (2014)
10.1016/j.jconrel.2011.10.003
Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
D. Zucker (2012)
10.1021/bc400517j
Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles.
O. Seifert (2014)
10.2147/IJN.S24847
The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals
Y. Men (2011)
10.3109/1061186X.2010.492525
Chondroitin sulfate functionalized liposomes for solid tumor targeting
Rashmi Bagari (2011)
10.3109/03639045.2015.1070171
Ocular delivery systems for topical application of anti-infective agents
L. Duxfield (2016)
10.1126/SCIENCE.432641
Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors.
J. Weinstein (1979)
10.1002/jps.24019
Preparation, characterization, and pharmacodynamics of thermosensitive liposomes containing docetaxel.
H. Zhang (2014)
10.1016/j.addr.2012.06.012
Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy.
Ju Hee Ryu (2012)
10.1016/j.jconrel.2010.10.017
Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug.
G. Shim (2011)
10.2147/IJN.S56070
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression
W. Gao (2014)
10.1016/j.canlet.2012.06.008
Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition.
Alexander Koshkaryev (2013)
Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.
E. T. Dams (2000)
10.1021/mp100380y
Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.
Y. Iwase (2011)
10.1038/nrc1456
High interstitial fluid pressure — an obstacle in cancer therapy
C. Heldin (2004)
10.1084/jem.20032220
In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination
L. Bonifaz (2004)
10.1166/JBN.2014.1837
Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study.
W. Yuan (2014)
10.1016/j.ijpharm.2010.07.053
A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice.
Zheng-Hua Zhong (2010)
10.2147/IJN.S53310
GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation
Liang Cheng (2014)
10.1021/nn300524f
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.
Lin Zhu (2012)
10.2174/156652411800615153
Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma.
S. Wu (2011)
10.1021/ar2000056
Theranostic nanoparticles engineered for clinic and pharmaceutics.
Xiaowei Ma (2011)
10.1371/journal.pone.0013430
Bioreducible Liposomes for Gene Delivery: From the Formulation to the Mechanism of Action
G. Candiani (2010)
10.1021/BC9801124
Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.
A. Gabizon (1999)
10.1002/jmri.24628
Molecular imaging of angiogenesis to delineate the tumor margins in glioma rat model with endoglin‐targeted paramagnetic liposomes using 3T MRI
Long-Hua Qiu (2015)
10.1038/mt.2008.51
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA.
Shyh-Dar Li (2008)
10.1097/CJI.0000000000000022
Targeted siRNA Silencing of Indoleamine 2, 3-Dioxygenase in Antigen-presenting Cells Using Mannose-conjugated Liposomes: A Novel Strategy for Treatment of Melanoma
D. Chen (2014)
10.1021/mp100171c
Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.
Rui Kuai (2010)
10.1016/J.JCONREL.2007.02.010
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Xinyu Wang (2007)
10.1038/nrd3137
Targeting mitochondria for cancer therapy
S. Fulda (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar